PortalPublikationenMechanisms of resistance to anti-angiogenic therapy and deve...

Mechanisms of resistance to anti-angiogenic therapy and development of third-generation anti-angiogenic drug candidates

Standard

Mechanisms of resistance to anti-angiogenic therapy and development of third-generation anti-angiogenic drug candidates. / Loges, Sonja; Schmidt, Thomas; Carmeliet, Peter.

in: Genes Cancer, Jahrgang 1, Nr. 1, 01.2010, S. 12-25.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Loges, S, Schmidt, T & Carmeliet, P 2010, 'Mechanisms of resistance to anti-angiogenic therapy and development of third-generation anti-angiogenic drug candidates', Genes Cancer, Jg. 1, Nr. 1, S. 12-25. https://doi.org/10.1177/1947601909356574

APA

Loges, S., Schmidt, T., & Carmeliet, P. (2010). Mechanisms of resistance to anti-angiogenic therapy and development of third-generation anti-angiogenic drug candidates. Genes Cancer, 1(1), 12-25. https://doi.org/10.1177/1947601909356574

Vancouver

Loges S, Schmidt T, Carmeliet P. Mechanisms of resistance to anti-angiogenic therapy and development of third-generation anti-angiogenic drug candidates. Genes Cancer. 2010 Jan;1(1):12-25. https://doi.org/10.1177/1947601909356574

Bibtex

@article{2f694b4a513f4ccea04fb14096e81344,
title = "Mechanisms of resistance to anti-angiogenic therapy and development of third-generation anti-angiogenic drug candidates",
abstract = "The concept of inhibiting tumor neovessels has taken the hurdle from the bench to the bedside and now represents an extra pillar of anticancer treatment. So far, anti-angiogenic therapy prolongs survival in the order of months in some settings while failing to induce a survival benefit in others, in part because of intrinsic refractoriness or evasive escape. This review provides an update on recent mechanisms via which tumor and stromal cells induce resistance and discusses recent evolutions in the (pre)clinical development of novel third-generation anti-angiogenic agents to overcome this problem.",
keywords = "Journal Article",
author = "Sonja Loges and Thomas Schmidt and Peter Carmeliet",
year = "2010",
month = jan,
doi = "10.1177/1947601909356574",
language = "English",
volume = "1",
pages = "12--25",
journal = "Genes Cancer",
issn = "1947-6019",
publisher = "SAGE Publications",
number = "1",

}

RIS

TY - JOUR

T1 - Mechanisms of resistance to anti-angiogenic therapy and development of third-generation anti-angiogenic drug candidates

AU - Loges, Sonja

AU - Schmidt, Thomas

AU - Carmeliet, Peter

PY - 2010/1

Y1 - 2010/1

N2 - The concept of inhibiting tumor neovessels has taken the hurdle from the bench to the bedside and now represents an extra pillar of anticancer treatment. So far, anti-angiogenic therapy prolongs survival in the order of months in some settings while failing to induce a survival benefit in others, in part because of intrinsic refractoriness or evasive escape. This review provides an update on recent mechanisms via which tumor and stromal cells induce resistance and discusses recent evolutions in the (pre)clinical development of novel third-generation anti-angiogenic agents to overcome this problem.

AB - The concept of inhibiting tumor neovessels has taken the hurdle from the bench to the bedside and now represents an extra pillar of anticancer treatment. So far, anti-angiogenic therapy prolongs survival in the order of months in some settings while failing to induce a survival benefit in others, in part because of intrinsic refractoriness or evasive escape. This review provides an update on recent mechanisms via which tumor and stromal cells induce resistance and discusses recent evolutions in the (pre)clinical development of novel third-generation anti-angiogenic agents to overcome this problem.

KW - Journal Article

U2 - 10.1177/1947601909356574

DO - 10.1177/1947601909356574

M3 - SCORING: Journal article

C2 - 21779425

VL - 1

SP - 12

EP - 25

JO - Genes Cancer

JF - Genes Cancer

SN - 1947-6019

IS - 1

ER -